282 related articles for article (PubMed ID: 17713853)
1. The role of 3-O-methyldopa in the side effects of L-dopa.
Lee ES; Chen H; King J; Charlton C
Neurochem Res; 2008 Mar; 33(3):401-11. PubMed ID: 17713853
[TBL] [Abstract][Full Text] [Related]
2. Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
Onzawa Y; Kimura Y; Uzuhashi K; Shirasuna M; Hirosawa T; Taogoshi T; Kihira K
Biol Pharm Bull; 2012; 35(8):1244-8. PubMed ID: 22863920
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine metabolites on locomotor activities and on the binding of dopamine: relevance to the side effects of L-dopa.
Charlton CG; Crowell B
Life Sci; 2000 Apr; 66(22):2159-71. PubMed ID: 10834300
[TBL] [Abstract][Full Text] [Related]
4. Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices.
Chang WY; Webster RA
Br J Pharmacol; 1995 Nov; 116(6):2637-40. PubMed ID: 8590982
[TBL] [Abstract][Full Text] [Related]
5. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Nakazato T; Akiyama A
Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
[TBL] [Abstract][Full Text] [Related]
6. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Jul; 67(3):245-9. PubMed ID: 20302892
[TBL] [Abstract][Full Text] [Related]
7. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
Reches A; Fahn S
Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
[TBL] [Abstract][Full Text] [Related]
8. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
[TBL] [Abstract][Full Text] [Related]
9. Effects of homocysteine on the dopaminergic system and behavior in rodents.
Lee ES; Chen H; Soliman KF; Charlton CG
Neurotoxicology; 2005 Jun; 26(3):361-71. PubMed ID: 15935208
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro.
Chan SW; Dunlop RA; Rowe A; Double KL; Rodgers KJ
Exp Neurol; 2012 Nov; 238(1):29-37. PubMed ID: 22001774
[TBL] [Abstract][Full Text] [Related]
11. An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease.
Cai XY; Kong XM; Fang Q; Ning P; Xu YJ; Zhang B; Xue SR
Neurodegener Dis; 2012; 9(1):11-7. PubMed ID: 21876323
[TBL] [Abstract][Full Text] [Related]
12. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
13. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
14. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
Asanuma M; Miyazaki I
BMC Neurosci; 2016 Jul; 17(1):52. PubMed ID: 27456338
[TBL] [Abstract][Full Text] [Related]
15. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
Rose S; Jenner P; Marsden CD
Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
[TBL] [Abstract][Full Text] [Related]
16. Effects of harman and norharman on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells.
Yang YJ; Lee JJ; Jin CM; Lim SC; Lee MK
Eur J Pharmacol; 2008 Jun; 587(1-3):57-64. PubMed ID: 18457825
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
[TBL] [Abstract][Full Text] [Related]
18. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
19. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
20. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Männistö PT; Tuomainen P
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
